Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Introduction: Recent U.S. trends demonstrate sharp rises in adverse opioid-related health outcomes, including opioid use disorder (OUD), overdose, and death. Yet few affected people receive treatment for OUD and a minority of those who receive treatment are effectively retained in care. The purpose of this study was to examine duration of buprenorphine treatment for OUD following treatment initiation to identify risk factors for early discontinuation. Methods: We analyzed insurance claims from the 2013–2015 MarketScan multi-state Medicaid database. The sample included adults 18–64 years old with an OUD diagnosis in the 6 months before initiating buprenorphine treatment, defined as 6 months without a buprenorphine claim prior to the index buprenorphine claim (N=17,329 individuals). We used Cox proportional hazards regression to estimate risk of discontinuing treatment (>30 days without buprenorphine supply), and logistic regression to estimate the odds of persistent treatment for a minimum of 180 days. Results: Over one-quarter of the sample discontinued buprenorphine in the first month of treatment (N=4,928; 28.4%) and most discontinued before 180 days (N=11,189; 64.6%). In the proportional hazards model, risk factors for discontinuation included a lower initial buprenorphine dose (≤4mg; Hazard Ratio [HR]=1.72, p<.001), male sex (HR=1.19, p<.001), younger age (HR=1.34, p<.001), minority race/ethnicity (black HR=1.31, p<.001; Hispanic HR=1.24, p=.01; other HR=1.09, p<.001), capitated insurance (HR=1.21, p<.001), comorbid substance use disorders (alcohol HR=1.07, p=.04; non-opioid drugs HR=1.14, p<.001), hepatitis C (HR=1.06, p=.01), opioid overdose history (HR=1.20, p=.001), or any inpatient care (HR=1.22, p<.001) in the 6-month baseline period. In logistic models, these risk factors were similarly associated with significantly lower odds of treatment retention for at least 180 days. Conclusion: For Medicaid beneficiaries with OUD treated with buprenorphine, there is a need to implement treatment models that more effectively address barriers to treatment retention. These barriers are particularly challenging for minorities, younger individuals, and those with additional substance use disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6501e1 · Cited by 2,697
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Epidemiology of women and depression
Kessler, R. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00426-3 · Cited by 2,006 · cited 2×
“Since women have higher rates of depression (Eaton et al., 2012; Kessler, 2003) and are more likely to take antidepressants at all levels of depression severity (Pratt, Brody, & Gu, 2011), future studies could examine the relationships between sex, the prevalence and treatment of depression, and…”
BackgroundIncreases in drug and opioid overdose deaths — United States, 2000–2014
Rudd, R. A., Aleshire, N., Zibbell, J. E., & Gladden, R. M. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6450a3 · Cited by 1,859
Vital signs: changes in opioid prescribing in the United States, 2006-2015.
Guy, G. P., Zhang, K., Bohm, M. K., Losby, J., Lewis, B., Young, R., Murphy, L. B., & Dowell, D. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6626a4 · Cited by 1,117
Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,015
Moore, B. J., White, S., Washington, R., Coenen, N., & Elixhauser, A. (2017) · Medical Care · doi:10.1097/mlr.0000000000000735 · Cited by 827 · cited 1×
“HIV, hypertension, obesity, diabetes, heart failure, liver failure, pulmonary disease) and applies weights to each comorbidity according to its predictive relationship with mortality (Moore et al., 2017).”
BackgroundEaton, N. R., Keyes, K. M., Krueger, R. F., Balsis, S., Skodol, A. E., Markon, K. E., Grant, B. F., & Hasin, D. S. (2012) · Journal of Abnormal Psychology · doi:10.1037/a0024780 · Cited by 701 · cited 1×
“Since women have higher rates of depression (Eaton et al., 2012; Kessler, 2003) and are more likely to take antidepressants at all levels of depression severity (Pratt, Brody, & Gu, 2011), future studies could examine the relationships between sex, the prevalence and treatment of depression, and retention in buprenorp…”
BackgroundDrop-out from addiction treatment: A systematic review of risk factors
Brorson, H. H., Ajo Arnevik, E., Rand-Hendriksen, K., & Duckert, F. (2013) · Clinical Psychology Review · doi:10.1016/j.cpr.2013.07.007 · Cited by 654
Cited by
Development of a Cascade of Care for responding to the opioid epidemic.
Williams, A. R., Nunes, E. V., Bisaga, A., Levin, F. R., & Olfson, M. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1546862 · Cited by 332
Self-citationLin, L. A., Bohnert, A. S. B., Blow, F. C., Gordon, A. J., Ignacio, R. V., Kim, H. M., & Ilgen, M. A. (2021) · Addiction · doi:10.1111/add.15116 · Cited by 108
Park, T. W., Larochelle, M. R., Saitz, R., Wang, N., Bernson, D., & Walley, A. Y. (2020) · Addiction · doi:10.1111/add.14886 · Cited by 78
“Since discontinuation of buprenorphine treatment is so common(38,39), clinicians should be aware of factors that are associated with an increased risk of discontinuation.”
BackgroundMethadone and buprenorphine discontinuation among postpartum women with opioid use disorder
Schiff, D. M., Nielsen, T. C., Hoeppner, B. B., Terplan, M., Hadland, S. E., Bernson, D., Greenfield, S. F., Bernstein, J., Bharel, M., Reddy, J., et al. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.04.210 · Cited by 69
Barocas, J. A., Morgan, J. R., Wang, J., McLoone, D., Wurcel, A., & Stein, M. D. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa062 · Cited by 48
Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?
Dunphy, C., Peterson, C., Zhang, K., & Jones, C. M. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108784 · Cited by 41
Zhang, K., Jones, C. M., Compton, W. M., Guy, G. P., Evans, M. E., & Volkow, N. D. (2022) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21m14001 · Cited by 22
Metadata
- Authors
- Samples, H., Williams, A. R., Olfson, M., & Crystal, S.
- Venue
- Journal of Substance Abuse Treatment
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 95
- Pages
- 9-17
- ISSN
- 0740-5472 (ISSN-L)
- OpenAlex
- W2890254074
- Cited by
- 235
- References
- 49
- FWCI
- 13.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.